The combined treatment with chemotherapy and radiotherapy is the standard of care in Hodgkin's disease. In 1992, introduction of the ABVD regimen consisting of doxorubicin, bleomycin, vinblastine and dacarbazine, marked a step improving survival and reducing toxic effects including infertility, second malignancies and myelosuppression. With early stage being cured in 90% of the cases and advanced disease in 70-80%, the focus now is reducing the treatment related morbidities by de-escalating and individualizing treatments. In the 1950's, Hodgkin's Lymphoma started to be cured with radiotherapy (RT) and since then, this tool has become a part of the standard therapy, balancing toxicity with chemotherapy. Specific to early-stage Hodgkin's Disease, a few cycles of cytotoxic therapy are combined with limited RT to eradicate local disease. In addition to dose reduction, modern RT technology has led to radical changes in RT delivery, allowing more accurate targeting and conformal coverage while sparing normal tissues and avoiding unnecessary adverse effects. RT for lymphoma has developed from total nodal irradiation or involved-field RT to now involvednode and involved-site RT. For advanced stage Hodgkin's Lymphoma, the role of radiotherapy is limited to cases of bulky disease and partial response after chemotherapy. Future directions focus on maximizing the cure and minimizing collateral effects, de-escalating treatment, adapting PET response, and replacing toxic drugs effects by antibody-based drugs with promising results. This chapter review the clinical trials on management of, and the role of radiotherapy in early and advanced Hodgkin's disease. [ABSTRACT FROM AUTHOR]